1el0: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1el0]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EL0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1EL0 FirstGlance]. <br> | <table><tr><td colspan='2'>[[1el0]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EL0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1EL0 FirstGlance]. <br> | ||
</td></tr><tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1el0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1el0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1el0 RCSB], [http://www.ebi.ac.uk/pdbsum/1el0 PDBsum]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1el0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1el0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1el0 RCSB], [http://www.ebi.ac.uk/pdbsum/1el0 PDBsum]</span></td></tr> | ||
<table> | </table> | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
| Line 27: | Line 27: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Clark-Lewis, I | [[Category: Clark-Lewis, I]] | ||
[[Category: Crump, M P | [[Category: Crump, M P]] | ||
[[Category: Keizer, D W | [[Category: Keizer, D W]] | ||
[[Category: Lee, T W | [[Category: Lee, T W]] | ||
[[Category: Slupsky, C M | [[Category: Slupsky, C M]] | ||
[[Category: Sykes, B D | [[Category: Sykes, B D]] | ||
[[Category: Chemokine fold]] | [[Category: Chemokine fold]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
Revision as of 22:45, 22 December 2014
SOLUTION STRUCTURE OF THE HUMAN CC CHEMOKINE, I-309SOLUTION STRUCTURE OF THE HUMAN CC CHEMOKINE, I-309
Structural highlights
Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedI-309 is a member of the CC subclass of chemokines and is one of only three human chemokines known to contain an additional, third disulfide bond. The three-dimensional solution structure of I-309 was determined by (1)H nuclear magnetic resonance spectroscopy and dynamic simulated annealing. The structure of I-309, which remains monomeric at high concentrations, was determined on the basis of 978 experimental restraints. The N-terminal region of I-309 was disordered, as has been previously observed for the CC chemokine eotaxin but not others such as MCP-1 and RANTES. This was followed in I-309 by a well-ordered region between residues 13 and 69 that consisted of a 3(10)-helix, a triple-stranded antiparallel beta-sheet, and finally a C-terminal alpha-helix. Root-mean-square deviations of 0.61 and 1.16 were observed for the backbone and heavy atoms, respectively. A comparison of I-309 to eotaxin and HCC-2 revealed a significant structural change in the C-terminal region of the protein. The alpha-helix normally present in chemokines was terminated early and was followed by a short section of extended strand. These changes were a direct result of the additional disulfide bond present in this protein. An examination of the I-309 structure will aid in an understanding of the specificity of this protein with its receptor, CCR8. Human CC chemokine I-309, structural consequences of the additional disulfide bond.,Keizer DW, Crump MP, Lee TW, Slupsky CM, Clark-Lewis I, Sykes BD Biochemistry. 2000 May 23;39(20):6053-9. PMID:10821677[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References |
| ||||||||||||||